TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time until response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Distal small bowel pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Skin reactivity to allergen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Antihistamine use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Need for adjustment of expected date of delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Feeling worried about pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Not feeling relaxed about pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of syncope induced by HUTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay in onset of syncope during HUTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum fall in systolic blood pressure during HUTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of dogs not showing microfilariae of D. repens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety of Milbemax® in treated dogs
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of Chronic Kidney Disease (CKD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Systolic and diastolic arterial pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain scores during retrobulbar injection and operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of atopic dermatitis (AD) flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with no flares at 6 or 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean parasite clearance times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hyperhidrosis disease severity scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite cardiovascular outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of serious infections
Endpoint domain: Adverse events/effects
Primary endpoint: Total operative deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of spermicide use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of male condom use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diary completion frequency
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mortality within six weeks
Endpoint domain: Mortality/survival
Primary endpoint: Recognition accuracy of textual warning statements
Endpoint domain: Cognitive functioning
Primary endpoint: Improvement in adenoid-to-air passage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of methylated serum DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of survival
Endpoint domain: Mortality/survival
Primary endpoint: rate of moderate/severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-lasting effect of exercise program on groin pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: pedometer step counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hazard ratio for death
Endpoint domain: Mortality/survival
Primary endpoint: sustained changes in immunisation behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-operative dental anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: overall lesion complete response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of local skin reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in femoral neck BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes
Primary endpoint: Plasma NO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythrocyte GPX activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cholesterol/HDL-cholesterol (CHOL/HDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean arterial attenuation value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose-length product (DLP) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction time performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement after transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of antibiotic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: paretic fine motor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bilateral nonparetic consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interlimb coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of histamine-induced wheal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: bone defect fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate at first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time required to intubate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Enhancement of well-being (WHO-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in percent atheroma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Interleukin 1β levels in exhaled breath condensate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PSA decline after 3 months of enzalutamide therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunological outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improved cognitive flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved response inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence of artemether and lumefantrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug peak concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of CT-proET-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median total reduction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity profile
Endpoint domain: Adverse events/effects
Primary endpoint: 2h-Post Prandial Plasma Glucose (PPPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rescue analgesic requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in histological severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lowering of inflammatory blood parameters (ESR, CRP, orosomucoid)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: shape and symmetry of nasal tip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: size and symmetry of nostrils
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nasal width, columellar height, and nasal tip projection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of being a recurrent faller
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stimulant abstinence during active treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in β-cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Progression to insulin treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression to primary end point
Endpoint domain: Mortality/survival
Primary endpoint: Rate of change in Unified Parkinson's Disease Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Eye muscle reflectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apparent ticagrelor clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ticagrelor bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased help seeking attitudes and intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: degree of efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nociception-anti-nociception balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intentions toward a peer in a wheelchair
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: CK‐MB concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: myoglobin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of bone fractures
Endpoint domain: Adverse events/effects
Primary endpoint: mean BFS data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pulmonary capillary wedge pressure (PCWP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: myocardial velocities at the septum and RV free wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FHR baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: FHR variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of accelerations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of late gastric outlet obstruction
Endpoint domain: Adverse events/effects
Primary endpoint: MAL scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to perform bimanual activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in mood, anxiety, and energy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Consistent condom use with clients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative Fourier phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coupling strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonculprit artery flow (CTFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global CTFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Confidence in delivering lessons
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean number of lessons taught
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children receiving lessons
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived level of mental fatigue/burnout
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: CS-PFP change scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative risk of survival
Endpoint domain: Mortality/survival
Primary endpoint: Prenatal stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interference with same-day activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: C‐FGF23 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: TmP/GFR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: new-onset organ failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation with measured AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bias of estimated AUCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision of estimated AUCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height gain after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS neck pain intensity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of squamous epithelial cells identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of nucleated epithelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean size of DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intra‐operative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Normalization of vital clinical indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to total scabbing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: itching on day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activity on day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First cardiovascular event (CV event)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FOBT attendance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gastrointestinal hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Nd:YAG capsulotomy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: good clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total clinical score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Itching score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear levels of tryptase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: effectiveness of acarbose as an adjunctive agent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of events in symptomatic patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety symptoms cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in asthenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in sleep disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative mycologic cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FVC and FEV(1) percent predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tooth loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvascular diseases (nephropathy, neuropathy, retinopathy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: abnormal pSOM findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of change in depression symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-test assessment improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to prescribed medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiretroviral effect during monitoring period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial counts in children's stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of progression from IFG to diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disappearance of cysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cyst size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum CA125 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of delusional memories
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of ending of compensation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of file closure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: percentage change in the spectrophotometer a* value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: immediate pain scores
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of blisters
Endpoint domain: Adverse events/effects
Primary endpoint: Fractional Anisotropy (FA) in frontal lobes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Outpatient respiratory medications received
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Right atrial enlargement (RAE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QTc-interval duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: P-wave voltage and duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: stimulus discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilization of ACS among mothers of <5th percentile infants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cardiovascular events incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 10-year cardiovascular disease risks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: coronary plaque burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plaque area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: thin-cap fibroatheroma prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: spatial task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: decreased hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time-to-onset of PMDD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of PMDD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: portal blood velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: portal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean change from baseline to end-point on the CDRS-R total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Worsening of suicidal ideation from baseline
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of satisfactory effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of post-operative emergencies
Endpoint domain: Adverse events/effects
Primary endpoint: Serum 25(OH)D concentrations >75 nmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes